MedPath

Comparative Evaluation of the efficacy of Autologus melanocyte transfer along with PUVA therapy and PUVA therapy alone in vitiligo patients

Phase 3
Conditions
vitiligo.
disorders of pigmentation
Registration Number
IRCT138706111159N1
Lead Sponsor
Iran National Science Foundation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
20
Inclusion Criteria

no treatment method since prior to 6 months ago, age 11-60, treatment history for 3 months
Exclusion criteria: pregnancy, breast feeding, depigmented patch >5 squared cm, active vitiligo, infection on treated site, cloid history, Cobner reaction

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Repigmentation rate. Timepoint: 3 weeks, 3 months, 6 months after treatment. Method of measurement: perfect >90%, good 65-89%, moderate 25-64%, fair <25%.;Side effects. Timepoint: 3 weeks, 3 months, 6 months after treatment. Method of measurement: observation.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath